Spotlight On... Pearson returns to Valeant with promise to boost payer, government relations; FDA approves Roche's Gazyva in follicular lymphoma; PhRMA's new chief tackles a tough job; Novartis expands Afinitor's NET market; and more...

Valeant ($VRX) CEO J. Michael Pearson, sidelined for two months with pneumonia, is back--and he's got a new set of priorities to dig his company out of its current rut. Among them: Beef up relationships with payers, regulators and government officials, he said Sunday. More from FiercePharma

> The FDA has green-lighted Roche ($RHHBY) treatment Gazyva in certain patients with previously treated follicular lymphoma. Release

> PhRMA's new chief, Stephen Ubl, is taking on the role at a tough time for the industry, and so far, his statements on changing the story about pharma price hikes have been hit or miss, Forbes suggests. Report

> Novartis ($NVS) won a new use for its cancer therapy Afinitor as a treatment for patients with certain types of inoperable neuroendocrine tumors originating in the lungs or gastrointestinal tract. Release

> Boehringer Ingelheim and AbbVie ($ABBV) are said to be in talks for a cancer-focused partnership; the German drugmaker sells two lung cancer meds and is studying new products for lung and bowel cancer, while AbbVie shares marketing of the blood cancer drug Imbruvica. Report

> Regeneron ($REGN) and Bayer's Eylea failed to hang onto its advantage over Roche's Lucentis at treating diabetic macular edema in the latest results from a two-year NIH-funded trial; at the one-year mark, Eylea appeared to deliver better gains in certain patients. Report

And Finally... China says it's planning to speed up the pace of its new drug approvals. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.